Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 65% Improvement Relative Risk Colchicine  Elshafei et al.  META ANALYSIS c19early.org Favors colchicine Favors control

Colchicine use might be associated with lower mortality in COVID‐19 patients: A meta‐analysis

Elshafei et al., European Journal of Clinical Investigation, doi:10.1111/eci.13645
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000056 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Meta analysis of 9 colchicine studies showing significantly lower mortality with treatment.
9 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, and severity Yasmin.
Currently there are 50 colchicine for COVID-19 studies, showing 29% lower mortality [18‑38%], 29% lower ventilation [-15‑56%], 25% lower ICU admission [3‑43%], 17% lower hospitalization [7‑25%], and 9% more cases [-8‑29%].
risk of death, 65.0% lower, OR 0.35, p < 0.001, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elshafei et al., 18 Jul 2021, peer-reviewed, 7 authors. Contact: dr.m.oraiby@hotmail.com.
This PaperColchicineAll
Colchicine use might be associated with lower mortality in COVID‐19 patients: A meta‐analysis
Mohamed Nabil Elshafei, Ahmed El‐bardissy, Ahmed Khalil, Mohammed Danjuma, Mahmood Mubasher, Ibrahim Y Abubeker, Mouhand F H Mohamed
European Journal of Clinical Investigation, doi:10.1111/eci.13645
Background: Colchicine was recently repurposed for the management of coronavirus disease 2019 (COVID-19). This rapid review and meta-analysis aimed to assess colchicine's impact on mortality outcomes in COVID-19 patients. Materials and Methods: We systematically searched PubMed, EMBASE, Google Scholar since their inception till 25/03/2021 for observational or controlled studies that reported mortality as an outcome. The mortality odd ratios were generated with their corresponding 95% confidence intervals utilizing the random-effects model. Results: Nine studies comprising 5522 patients met our inclusion criteria. Our metaanalysis revealed significantly lower mortality in the colchicine group (OR 0.35, 95% CI 0.25-0.48, I2 0%) compared with controls. A subgroup analysis limited to hospitalized patients (OR 0.35, 95% CI 0.25-0.50, I2 0%) revealed similarly lower mortality in the colchicine group. Conclusions: This meta-analysis suggests a mortality benefit with colchicine when used in the treatment of COVID-19 patients. The majority of included studies were observational; thus, the findings of this review need to be further supported by the results of ongoing trials.
CONFLICT OF INTEREST None declared by all authors. AUTHOR CONTRIBUTIONS ETHICAL APPROVAL No ethical approval is necessary as this was a secondary synthesis of published articles.
References
Aimo, Figal, Bayes-Genis, Emdin, Georgiopoulos, Effect of low-dose colchicine in acute and chronic coronary syndromes: a systematic review and meta-analysis, Eur J Clin Invest, doi:10.1111/eci.13464
Brunetti, Diawara, Tsai, Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19, J Clin Med, doi:10.3390/jcm9092961
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw open, doi:10.1001/jamanetworkopen.2020.13136
Elshafei, Khalil, El-Bardissy, Danjuma, Ahmed et al., The efficacy of colchicine in the management of coronavirus disease 2019: A protocol for systematic review and meta-analysis, Medicine, doi:10.1097/MD.0000000000021911
García-Posada, Vesga, Mestra, Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean, J Infect Public Health, doi:10.1016/j.jiph.2021.02.013
Kimmig, Wu, Gold, IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections, Front Med, doi:10.3389/fmed.2020.583897
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, doubleblinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Mahale, Rajhans, Godavarthy, A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital, Indian J Crit Care Med, doi:10.5005/jp-journals-10071-23599
Manenti, Maggiore, Fiaccadori, Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. Cannatà A, PLoS ONE, doi:10.1371/journal.pone.0248276
Mareev, Orlova, Plisyk, Proactive antiinflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiia, doi:10.18087/cardio.2021.2.n1560
Mohamed, Sd, Shunnar, Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis, Front Cardiovasc Med, doi:10.3389/fcvm.2020.598846
Pinzón, Doris Cardona Arango, Betancur, Clinical Outcome of Patients with COVID-19
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection, Can J Infect Dis Med Microbiol, doi:10.1155/2020/8865954
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217712
Tardif, Bouabdallaoui, Allier, Efficacy of colchicine in non-hospitalized patients with COVID-19, doi:10.1101/2021.01.26.21250494
Wichmann, Sperhake, Lütgehetmann, Autopsy findings and venous thromboembolism in patients with COVID-19
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit